3 results
Approved WMOCompleted
Primary Safety Objective * Proportion of patients who complete 24 weeks of combination treatment on pirfenidone at a dose of 1602*2403 mg/d and nintedanib at a dose of 200*300 mg/d Secondary Safety Objective * Proportion of patients who discontinue…
Approved WMOCompleted
To determine the accuracy of Vasovist® enhanced MRA of the leg with regard to quantitative grading of stenosis (<50%, >=50%) compared to digital subtraction angiography (DSA, standard of reference (SOR))
Approved WMOWill not start
To determine the efficacy of subcutaneous administration of brodalumab compared with placebo in treating adolescents with moderate-to-severe plaque psoriasis.